Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation

Srividya Gurumurthy, Geetha Iyer, Bhaskar Srinivasan, Shweta Agarwal, Narayanasamy Angayarkanni

ABSTRACT
To study the tear cytokine and the conjunctival and oral mucosal marker profile in chronic ocular Stevens-Johnson syndrome (SJS) and their alteration following mucous membrane grafting (MMG) for lid margin keratinisation (LMK).

Methods In a 1-year prospective study, SJS cases (n=25) and age-matched/sex-matched healthy controls (n=25) were recruited. Tear specimens were collected from controls and SJS cases pre-MMG and post-MMG (at first follow-up, n=17). Tear cytokines were profiled using 27-bioplex array. Transforming growth factor-beta (TGF-β)-mediated extracellular matrix changes in conjunctival and oral mucosal cells were analysed by gene expression studies.

Results Tear cytokine profiling of chronic SJS cases at pre-MMG stage revealed significant upregulation of cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-8, IL-1β, monocyte chemotactic protein-1, IL-12, IL-17A and basic fibroblast growth factor (bFGF) with downregulation of IP-10 (interferon gamma-induced protein 10), tumour necrosis factor-α, interferon-γ, IL-10, vascular endothelial growth factor, regulated upon activation normal T-cell expressed and secreted (RANTES), IL-7, IL-12p70 and IL-13, with maximal increase in GM-CSF and maximal downregulation of IP-10, respectively. Of these, IL-2, IL-15, bFGF and IL-17A showed significant correlation with disease severity, pre-MMG. Conjunctival cells pre-MMG showed increase in TGF-β1, TGF-βII, connective tissue growth factor and collagen-III gene expression by 10, 67, 173 and 184 folds, respectively, which dropped to 1.3, 11, 13.5 and 19 folds correspondingly, post-MMG. However, their expressions in oral mucosa were negligible.

Conclusion A proinflammatory, profibrotic, antiangiogenic ocular surface milieu characterises chronic ocular SJS. IP-10, an antiangiogenic cytokine was noted to be maximally downregulated, unlike in other forms of chronic dry eye disease. The alterations in the ocular surface are seen to reverse largely with MMG for LMK. The ocular sequelae of SJS causes visual debilitation due to chronic inflammatory changes occurring on the ocular surface as well as significant functional impairment due to associated symptoms like photophobia, dryness and foreign body sensation.

LMK keratinisation (LMK), a feature that occurs in most eyes of patients with SJS has been identified as an important cause for the continued inflammation and deterioration of the ocular surface as published in earlier reports, if not intervened in the acute stage with amniotic membrane grafting. 1-3 Our earlier study on the comprehensive management for SJS highlighted the beneficial impact of mucous membrane grafting (MMG) for LMK. 3 A cytokine storm in the tear samples from a patient of acute SJS has been reported earlier. 4 However, there are no reports on the tear cytokine expression in the chronic phase of SJS. Therefore, this study aims to understand the same in eyes with chronic sequelae of SJS including LMK and their alteration following MMG.

METHODS
Patients and healthy controls
A prospective study at a tertiary eye care centre was conducted between May 2014 and April 2015 in adherence to the tenets of the Declaration of Helsinki, with informed consent from study recruits and following approval from the Institutional Review Board. Chronic SJS cases with LMK warranting mucous membrane graft were included in the study. All patients with SJS underwent a detailed ocular examination and the parameters analysed were: best-corrected visual acuity; Schirmer’s I test (graded as 1, <5 mm; 2, 5–10 mm; 3, 11–15 mm and 4, >15 mm) and fluorescein corneal staining scores from 0 to 9. The diagnosis of SJS was based on a confirmed history of acute onset of high fever, serious mucocutaneous illness with skin eruptions and involvement of at least two mucosal sites including the ocular surface. Inclusion criteria included all eyes with LMK that warranted MMG, excluding eyes with total limbal stem cell deficiency, grade 3 or worse slymphobrachon5 and total keratinisation of the ocular surface.

Samples from patients with SJS were collected preoperatively (n=50 eyes) and postoperatively (n=33 eyes) at their first follow-up visit prior to performing any other ophthalmic investigations which included tear collection, conjunctival imprint.
from four quadrants and oral mucosal imprint cytology from the lip. The enrolled patients were only on artificial tear substitutes preintervention and postintervention at the time of sample collection. Topical antibiotics started postoperatively were stopped at 1 week following surgery. The MMG for LMK was performed as described earlier.3

Healthy volunteers (n=50 eyes), age-matched/sex-matched to the cases, were the control group, selected using inclusion criteria namely, absence of ocular surface-related symptoms; and Schirmer’s wetting of >10mm at 5 min. Exclusion criteria included any history of ophthalmic or systemic disease, ocular allergy, ophthalmic surgery and currently under medication/pregnancy/contact lens wear.

Tear sample collection and extraction
The tear samples were collected and extracted from the Schirmer's strips to the method described earlier, except that extraction was done in IX phosphate buffered saline (PBS) with 0.1% Triton X-100.6

Multiplex analysis of cytokines in tear samples
A Bio-Plex multiplex assay (Bio-Plex Human Cytokine 27-plex panel, Bio-Rad Laboratories, Hercules, California, USA) was used to measure the concentrations of 27 cytokines in tear from patients with SJS and healthy controls. Following extraction, the total protein concentration was adjusted to 500 µg/mL with 1X PBS and 25 µL was taken uniformly for Bio-Plex analysis. The analysis was performed according to the manufacturer’s instructions and read in Bio-Plex Reader (Bio-Rad Laboratories). Standard curves were generated using the Bio-Plex Manager System (software V.6.0; Bio-Rad Laboratories) to calculate the cytokine concentrations in the tear samples.

Quantitative PCR
Total RNA was isolated from the imprints using Tripure RNA isolation reagent (Roche Diagnostics, Basel, Switzerland) according to manufacturer’s protocol. One µg of DNaseI (New England Biolabs, Ipswich, Massachusetts, USA) treated total RNA from conjunctival or oral mucosal imprints were used for complementary DNA (cDNA) synthesis using iScript cDNA synthesis kit (Bio-Rad Laboratories). The gene-specific primers were designed for the genes 18S rRNA, α-smooth muscle actin (α-SMA), vimentin, Bax, Bcl2, β-actin and α-tubulin (see online supplementary table 1). Real-time PCR was performed with the Lightcycler 96 (Roche Diagnostics, Switzerland) using the SYBR Green chemistry. The comparative 2^{ΔΔCt} method was used to analyse the results of the genes of interest relative to internal control gene (18 rRNA).

Western blot analysis
Total protein was extracted from the imprints by incubating them in extraction buffer (10mM Tris buffer (pH 8.0), 0.2% Triton X-100, 10% glycerol, 0.5 mM EDTA, 1mM dithiothreitol with protease inhibitor cocktail) for 10 min followed by centrifugation at 8000 rpm for 5 min. The total protein concentration was determined using BCA protein assay kit (Pierce Biotechnology, Waltham, Massachusetts, USA) and 30 µg was loaded onto 10% SDS PAGE and transferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories). The antibodies used included rabbit anti-α-SMA antibody (Abcam, Cambridge, UK), rabbit anti vimentin antibody (Abcam) at a dilution of 1:500 or mouse anti-β-actin (Santa Cruz Biotechnology (SCBT), Santa Cruz, California, USA) or mouse anti-α-tubulin (SCBT) at a dilution of 1:1000. The membrane was washed and incubated with either anti rabbit/anti mouse IgG-HRP conjugated secondary antibody (SCBT). The blots were developed with Clarity TM Western ECL substrate (Bio-Rad Laboratories) and the images captured using FlourChem FC3 gel documentation system (Protein Simple, San Jose, California, USA). Intensity of band was assessed using ImageJ software (NIH, Bethesda, Maryland, USA). α-Tubulin was used as loading control.

Immunofluorescence
Conjunctival imprints from patients with SJS and controls were fixed with 4% paraformaldehyde for 20 min at room temperature. The fixed cells were washed twice with wash buffer (0.1% bovine serum albumin (BSA) in 1X PBS), permeabilised in 1X PBS+0.1% Tween 20 and blocked with 1% BSA for 30 min at room temperature. The imprints were then incubated with primary rabbit anti vimentin/anti-α-SMA/ mouse anti-α-tubulin (1:200), in dilution buffer (1X PBS, 1% BSA) at room temperature for 2 hours. The imprints were washed twice and incubated with corresponding fluorescein isothiocyanate-conjugated secondary antibodies (1:500, Invitrogen, Carlsbad, California, USA) for 1 hour in dark. Imprints were washed and counter-stained with 4,6-diamidino-2-phenylindole for 3 min in dark. After phosphate-buffered saline Tween 20 washes, the imprints were mounted on a glass slide using antifade mounting medium (Invitrogen) and observed under confocal microscope.

Collection of conjunctival and oral mucosal imprints
Imprints from the superior, inferior and temporal bulbar conjunctiva (pre-MMG/post-MMG) and lower lip (pre-MMG) were collected according to the method described by Gadkari et al.7 H&E staining was done in conjunctival and oral mucosal imprints in a subset of three SJS cases, pre-MMG and at first and second follow-up visit post-MMG to observe the cell phenotype. Similarly, periodic acid Schiff staining was done to assess the presence of goblet cells in the conjunctival imprints.

Statistical analyses
Data were expressed as mean±SD, the median and range. The statistical analyses were performed using SPSS for Windows V.14.0. The Pearson’s χ² test was used to compare the proportions of qualitative variables. D’Agostino-Pearson omnibus K2 normality test was used to check the normal distribution of the data. Student’s t-test and the Mann-Whitney U test were used to compare the means of the quantitative variables between two independent groups. The Kruskal-Wallis test was used to compare multiple groups. Fold variation of >1.2 folds and in 50% of cases compared with controls were considered significant.

One-way analysis of variance (ANOVA) was used to assess the correlation between causative factor, intervention period or disease duration with SJS severity. A p Value <0.05 was accepted as statistically significant.

RESULTS
Patients with SJS (n=25, 50 eyes; 12 males/13 females; mean age: 30.88±11.42 years) and healthy controls (n=25, 50 eyes; 12 males/13 females; mean age: 30.16±7.77 years) were recruited in the study. The controls were age-matched/sex-matched volunteers (see online supplementary table 1). Of the 25 patients, post-MMG samples were collected in 17 patients (33 eyes) at the first follow-up visit between 2 and 3 months (except 1 at 8
months) following surgery. After the mucous membrane graft, the corneal fluorescein staining score improved ≥3 in 84.48% of eyes. The details of demographic/clinical characteristics of the patients are documented in online supplementary table 2.

Pro-inflammatory and anti-inflammatory cytokine levels in tears

All the 27 cytokines were detectable in the tear samples (see online supplementary table 3). Differential expression analysis of the cytokines in SJS cases prior to MMG revealed eight cytokines to be significantly upregulated and nine to be significantly downregulated (figure 1). The distribution analysis of the upregulated ones revealed maximal increase in GM-CSF and among downregulated ones, IP-10 (interferon gamma-induced protein 10) was maximal. More than 80% of SJS cases showed upregulated cytokines that were significantly altered (table 1).

On analysing the gender effect on the differential expression, it was observed that IL-6 levels were twofold (p=0.008) increased and RANTES (regulated upon activation normal T-cell expressed and secreted) levels were 2.75 folds (p=0.009) decreased in the female SJS cases. However, on combining the male and female data, while RANTES was still significantly lower in SJS; IL-6 levels was not significantly increased in patients compared with controls pre-MMG. No other cytokine showed any gender bias.

Cytokine expressions at follow-up after MMG intervention

An overall improvement of around 48% (mean 48%±12%) was seen in the levels of all cytokines post-MMG, although IL-7,

Figure 1  Distribution of cytokines in Stevens-Johnson syndrome cases as compared with controls. (A) Overexpressed cytokines. (B) Underexpressed cytokines. ***p<0.001. bFGF, basic fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; IFN-γ, interferon-γ; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumour necrosis factor-α; VEGF, vascular endothelial growth factor.
evaluation of fibrotic markers in SJS conjunctiva pre-MMG and post-MMG

Cytokine expression profile in chronic SJS cases pre-MMG was indicative of defective wound healing resulting in fibrosis. The expression of both α-SMA and vimentin were higher in the conjunctival imprints of patients with SJS (pre-MMG) indicating myofibroblast formation (figure 3A). The protein expressions of the fibroblast markers, α-SMA and vimentin were concomitant to the changes in the corresponding mRNA levels as seen in the conjunctival imprint samples of SJS cases in preintervention and postintervention stages (figure 3B). As the LMK is addressed by grafting oral mucosal tissue following excision of keratinised lid margin conjunctiva, the gene expression for TGF-β signalling was assessed preintervention and postintervention in the conjunctival cells, as well as in the oral mucosa pre-MMG. Accordingly, the expressions of TGF-β1 and its receptors, TGF-βRI, TGF-βRII and the downstream signalling molecules, CTGF and collagen-III were found to be higher in SJS, which reduced post-MMG. This expression pattern was seen in >56% of the cases (figure 3C(i)). The expressions of TGF-β1, CTGF and collagen-III were 4, 16 and 7 folds lower, while that of TGF-βRII was 67 times higher in the oral mucosa of SJS cases than in the conjunctiva (figure 3C(ii)). Thus, the high TGF-βRII expression was differential in the patient’s conjunctiva compared with oral mucosa apart from the low TGF-β1 and CTGF expression. The expressions of TGF-β1, its receptors and downstream molecules studied were negligible in the control mucosa (data not shown).

Evaluation of apoptotic markers in conjunctiva

As both pro-apoptotic and anti-apoptotic cytokines were low in SJS, mRNA expressions of the apoptotic markers Bax (pro-apoptotic) and Bcl2 (anti-apoptotic) were checked in the conjunctival imprint samples, which showed a net promotion of apoptosis post-MMG (figure 3D).

Clinical correlation

The correlation between causative factor, intervention period or disease duration with SJS severity was determined using one-way ANOVA. Our results demonstrated that the SJS severity significantly correlated with the disease duration, but not with the causative factor or intervention period. Spearman’s rank-order correlation coefficients were used to assess the relationship between the concentrations of the assayed cytokines and SJS severity, which revealed that IL-2, IL-15, IL-17A and bFGF significantly correlate with the disease severity, at the preintervention stage (p<0.05).

DiScussioN

There are no earlier published reports on the tear cytokine profile in chronic SJS. Cutaneous lesions have been examined and reported.8 Previous report of selected tear cytokines

Table 1 Differentially expressed cytokines in SJS cases

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Fold change in cytokine Mean±SD (range)</th>
<th>95% CI</th>
<th>% cases above/ below median of control*</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Increased expression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GM-CSF</td>
<td>29.02±19.93 (1.02–57.33)</td>
<td>31.43 to 41.41</td>
<td>84.22</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-8</td>
<td>17.13±24.40 (1.23–182)</td>
<td>11.27 to 37.29</td>
<td>89.51</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-1β</td>
<td>13.27±24.40 (1.44–133)</td>
<td>7.17 to 26.28</td>
<td>81.58</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>MCP-1</td>
<td>4.77±8.78 (1.02–37.56)</td>
<td>1.99 to 7.12</td>
<td>94.77</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-15</td>
<td>2.8±1.82 (1.25–6.08)</td>
<td>2.74 to 3.86</td>
<td>76.32</td>
<td>0.018</td>
</tr>
<tr>
<td>IL-2</td>
<td>2.71±1.46 (1.00–4.57)</td>
<td>2.21 to 3.09</td>
<td>92.40</td>
<td>0.0089</td>
</tr>
<tr>
<td>IL-17</td>
<td>2.03±1.20 (1.00–4.67)</td>
<td>1.94 to 2.6</td>
<td>84.22</td>
<td>0.0007</td>
</tr>
<tr>
<td>bFGF</td>
<td>2.0±1.12 (1.08–4.19)</td>
<td>2.04 to 2.66</td>
<td>84.22</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Decreased expression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td>−2.13±0.92 (1.21–14.28)</td>
<td>−7.10 to −4.11</td>
<td>68.43</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TNF-α</td>
<td>−1.34±0.52 (−1.09– −6.08)</td>
<td>−2.70 to −1.92</td>
<td>73.69</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-10</td>
<td>−1.47±0.40 (−9.09–1.77)</td>
<td>−3.14 to −1.92</td>
<td>82.97</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>−1.52±0.48 (−1.09– −20)</td>
<td>−5.24 to −2.20</td>
<td>76.32</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RANTES</td>
<td>−1.73±0.56 (−3.29–1.79)</td>
<td>−3.86 to −2.08</td>
<td>73.69</td>
<td>0.0010</td>
</tr>
<tr>
<td>IL-7</td>
<td>−2.02±0.48 (−1.07– −50)</td>
<td>−6.41 to −2.61</td>
<td>81.58</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-13</td>
<td>−2.11±0.53 (−1.06– −50)</td>
<td>−9.33 to −2.27</td>
<td>84.22</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-12p70</td>
<td>−2.12±0.37 (−1.08– −16.60)</td>
<td>−5.13 to −1.92</td>
<td>86.85</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IP-10</td>
<td>−2.68±0.94 (−1.21– −5000)</td>
<td>−1012.07 to −168.08</td>
<td>86.85</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*Above median of control in case of increased expression and below in case of decreased expression level.

bFGF, basic fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; IFN-γ, interferon-γ; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated upon activation normal T-cell expressed and secreted; SJS, Stevens-Johnson syndrome; TNF-α, tumour necrosis factor-α; VEGF, vascular endothelial growth factor.
from a single patient in the acute stage of SJS showed elevated levels of IL-8, IL-6, TNF-α and CCL2 marking the initiation of the inflammatory process. There are currently no specific antidotes for the chronic ocular sequelae of the disease. A better understanding of the bioclinical changes in these eyes could highlight the pathophysiology and hence the possibility for targeted treatment options. In our earlier study, LMK was noted to be the most common manifestation in these eyes along with other signs like dryness, symblephara and features suggestive of limbal stem cell deficiency. The rationale of MMG in eyes with LMK is to eliminate the lid-wiper induced epitheliopathy and continued limbal stem cell damage. Hence, this study focused on the tear and conjunctival cytokine profile in chronic SJS cases with LMK and the alteration in the same following MMG to understand any additional reparative factors contributed by the mucosa. In the chronic stage of SJS, we observed an

Figure 2  Cytokine expressions premucous membrane grafting (MMG) and post-MMG. (A) Cytokines overexpressed pre-MMG. (B) Cytokines underexpressed pre-MMG. ***p<0.001. bFGF, basic fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; IFN-γ, interferon-γ; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumour necrosis factor-α; VEGF, vascular endothelial growth factor.
altered cytokine profile characterised by dysregulated immune response, decrease of pro-apoptotic activity and an increased fibrotic state (figure 4).

**Pro-inflammatory factors**
All the patients with SJS recruited in this study had LMK at the time of presentation and showed a typical pro-inflammatory profile in their tears with increased expressions of GM-CSF, bFGF, IL-8, IL-1β, IL-17A and TGF-β1. The tear cytokine profile is suggestive of preponderance of fibrosis causing Th17 cells due to persistent inflammation along with lowered expression of the anti-inflammatory cytokines such as IL-10 and IL-13 possibly resulting in LMK.9

**Profibrotic factors**
A persistently inflamed state is known to cause epithelial-to-mesenchymal transition (EMT) changes, a process that is integral to organogenesis, wound healing and cancer progression. However, uncontrolled EMT changes cause aberrant wound healing by induction of proteases and matrix protein degradation.10 α-SMA is a specific marker of myofibroblast differentiation in the fibrotic tissue.11 This study shows that the potent inducers of EMT, namely, TGF-β1, IL-1β, IL-8, IL-17A are upregulated. The chronic SJS cases in our study showed fibrosis as seen by increased expressions of CTGF and collagen-III as well as mesenchymal markers vimentin and α-SMA in the imprints of conjunctival cells. β-Actin expression was found to be lost in the conjunctival cells of the chronic SJS. Poor β-actin expression reported in myofibroblasts is associated with impaired repair mechanism.12

**Antifibrotic/anti-apoptotic factors**
Furthermore, the antifibrotic cytokines IP-10, IFN-γ, IL-12p70 and TNF-α that are known to limit fibrosis as reported in

---

**Figure 3**  Fibrotic and apoptotic marker expressions in Stevens-Johnson syndrome (SJS) conjunctiva.
bleomycin-induced pulmonary fibrosis, were downregulated, clearly favouring the fibrotic events characteristic of chronic SJS. These specific changes in the tear cytokine are contrary to the findings in chronic dry eye disorders, where these factors tend to be upregulated. Although the cutaneous expression of TNF-α is reported to be high in SJS/TEN, the tear TNF-α levels were found to be lowered in the SJS cases in this study. Macrophage in prohealing phenotype has been associated with lowering of TNF-α and this can induce a profibrotic process. The decreased TNF-α along with reduced IFN-γ and IP-10 in extreme cases, could lead to a severe smouldering inflammation and progressive subconjunctival fibrosis mimicking the clinical features of ocular cicatricial pemphigoid.

**Post-MMG alteration in cytokine profile**

Post-MMG, the levels of most of the pro-inflammatory cytokines declined with a concomitant improvement in the anti-inflammatory ones. Sustained increase of α-SMA post-MMG indicates the proliferative phase of wound healing. This probably is downregulated with time that needs evaluation in further follow-ups. IFN-γ which is lowered in SJS pre-MMG improves fivefold with MMG intervention. IFN-γ is reported to exert anti-inflammatory effects by various mechanisms including the suppression of differentiating monocyte/macrophages, inhibits IL-1β-mediated production of matrix metalloproteinases and suppress IL-17. Additional studies are warranted on the role of TNF-α and IFN-γ in the acute versus chronic stages of SJS for therapeutic implications.

**Role of oral mucosal grafting**

The macrophage functional phenotype can be altered with alteration in the microenvironment. With appropriate stimulus, it can result in altered production of cytokines, metabolites and enzymes that can have a healing outcome. Oral mucosal squamous epithelial cells are known to have a unique...
immune homeostasis in the oral cavity, where severe inflammatory responses in the oral cavity are relatively rare and tolerance to microbial load is relatively high. The exact mechanism by which MMG impacts the ocular surface besides eliminating the mechanical lid-wiper effect of LMK is yet to be studied in detail, although our study has shown the profibrotic factors to be much lower in the oral mucosa of patients with SJS compared with the conjunctiva.

Salient findings of this study
The principal findings of this study are: (1) profibrotic, pro-inflammatory, anti-apoptotic baseline ocular surface milieu with significantly decreased IP-10, TNF-α and IFN-γ levels, which could therefore be a potential candidate(s) in chronic SJS for targeted therapy; (2) reversal of most of the cytokine profile following MMG, correlating with the clinical improvement; (3) contribution of antifibrotic/anti-inflammatory factors by the oral mucosal niche; (4) an increase in goblet cell density following MMG, the exact underlying mechanism of which is yet to be elucidated.

Limitations of this study include lack of corroboration with the serum cytokine profile in the chronic stage and a comparison with other cicatricial conditions like ocular cicatricial pemphigoid, although similar findings have been documented in CGVHD, a condition not so commonly seen in our setting, indicative of a possible similar common pathway in the chronic stage of ocular cicatricial conditions, which are preceded by an acute event. However, further studies are required to understand the switch from the acute to chronic stage, in both the tears and serum.

CONCLUSION
The ocular surface biochemical profile in chronic SJS appears to be distinct from that in the acute stage. With the profile of the oral mucosa noted in our study, grafting of the oral mucosa could create a new niche beneficial to the conjunctiva by altering its milieu so as to contribute, in addition to elimination of the mechanical sandpaper effect of the LMK, an improvement in the inflammation and decrease in fibrosis, features that constitute the hallmark of chronic SJS.

Acknowledgements
The authors acknowledge International Centers for Excellence in Research at National Institute for Research in Tuberculosis, Chennai for the permission to use multiplex reader facility.

Contributors
5G contributed to the study protocol, conducted the experiment, analysed and integrated the data, wrote, proofed and revised the article. AN designed the study protocol, analysed and integrated the data, wrote, proofed and revised the article. GI and BS provided materials, designed the study protocol, analysed and integrated the data, proofed and revised the article. SA provided materials, analysed the data, proofed and revised the article.

Funding
The study is partly funded by the Department of Science & Technology SR/ WOS(A)/LS-1221/2014(G), Government of India.

Competing interests
None declared.

Patient consent
An institutional consent form was signed by all patients included, agreeing to be part of the study.

Ethics approval
Ethics Sub-Committee (Institutional Review Board) 388-2013-P.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES